改善老年弥漫性大B细胞淋巴瘤患者的生存率并预测毒性：微妙的平衡 - Suppr | 超能文献

Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.

作者信息

Smith Sonali M

机构信息

The University of Chicago, Chicago, IL.

出版信息

J Clin Oncol. 2021 Apr 10;39(11):1193-1195. doi: 10.1200/JCO.21.00202. Epub 2021 Mar 9.

DOI:10.1200/JCO.21.00202

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.改善老年弥漫性大B细胞淋巴瘤患者的生存率并预测毒性：微妙的平衡

J Clin Oncol. 2021 Apr 10;39(11):1193-1195. doi: 10.1200/JCO.21.00202. Epub 2021 Mar 9.

2

Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.在利妥昔单抗时代，治疗相关毒性对丙型肝炎病毒阳性弥漫性大B细胞淋巴瘤结局的影响。

Hematology. 2014 Oct;19(7):412-6. doi: 10.1179/1607845413Y.0000000147. Epub 2014 Jan 20.

3

Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.非霍奇金淋巴瘤：利妥昔单抗对弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤患者总生存的影响。

Arch Med Res. 2015 Aug;46(6):454-61. doi: 10.1016/j.arcmed.2015.07.004. Epub 2015 Jul 31.

4

A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.苯达莫司汀联合利妥昔单抗治疗既往未治疗的老年弥漫性大B细胞淋巴瘤的II期试验。

Br J Haematol. 2016 Oct;175(2):281-289. doi: 10.1111/bjh.14232. Epub 2016 Jul 22.

5

Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).在老年弥漫性大B细胞淋巴瘤患者中，R-CHOP诱导化疗四个周期后进行利妥昔单抗巩固治疗：淋巴瘤生存改善联盟研究（CISL）

Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.

6

Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?弥漫性大 B 细胞淋巴瘤的近期生存趋势——除了利妥昔单抗，我们还有其他进展吗？

Cancer Med. 2020 Aug;9(15):5519-5525. doi: 10.1002/cam4.3237. Epub 2020 Jun 18.

7

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.在标准化疗基础上加用利妥昔单抗可提高弥漫性大B细胞淋巴瘤生发中心B细胞样和非生发中心B细胞样亚型的生存率。

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.

8

Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.利妥昔单抗治疗后复发/难治性弥漫性大B细胞淋巴瘤的CD20表达及其对预后的影响

Asian Pac J Cancer Prev. 2018 Feb 26;19(2):331-335. doi: 10.22034/APJCP.2018.19.2.331.

9

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.配对分析比较利妥昔单抗联合化疗治疗原发性乳腺和淋巴结弥漫性大 B 细胞淋巴瘤患者的结局。

Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30.

10

Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.利妥昔单抗在高危弥漫性大B细胞淋巴瘤一线治疗中的作用：波兰淋巴瘤研究小组的回顾性分析

Pol Arch Med Wewn. 2015;125(10):741-8. doi: 10.20452/pamw.3113. Epub 2015 Sep 3.

引用本文的文献

1

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.20 家美国癌症中心的原发性中枢神经系统淋巴瘤老年患者：生存与预后分析。

Am J Hematol. 2023 Jun;98(6):900-912. doi: 10.1002/ajh.26919. Epub 2023 Apr 5.

2

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.SWOG 1918：一项在 75 岁或以上新诊断侵袭性非霍奇金淋巴瘤患者中进行的 R-miniCHOP 联合或不联合口服阿扎胞苷（CC-486）的 II/III 期随机研究-旨在改善治疗、结局，并验证一个前瞻性虚弱工具。

J Geriatr Oncol. 2022 Mar;13(2):258-264. doi: 10.1016/j.jgo.2021.10.003. Epub 2021 Oct 20.